Immediate Dental Implant PlacementADMNCT07573020
Influence of Acellular Dermal Matrix on Peri-implant Soft Tissue Phenotype and Marginal Bone Loss
A study testing Polytetrafluoroethylene coverage and Acellular Dermal Matrix in people with Immediate Dental Implant Placement and Dental Implant, run by Mansoura University at 1 site in Egypt.
Trial summary
To evaluate soft tissue augmentation using acellular dermal matrix (ADM) over immediately placed dental implants in anterior maxilla. Read more about this study
- Who is it for?
- Ages 18 to 45 years
- Conditions the study is for
- Immediate Dental Implant Placement, Dental Implant, Acellular Dermal Matrix
- What is being tested?
- Polytetrafluoroethylene coverage and Acellular Dermal Matrix
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Apr 2025to 1 Mar 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patients with non-restorable maxillary anterior tooth/teeth.
- Good oral hygiene.
- Patients' cooperation and fully capable to comply with the study protocol.
- Age ranges from 18 to 45 years.
- Free from history of parafunctional habits e.g. clenching and bruxism
- Sufficient inter- arch space.
Who cannot join
- Any local pathological condition that contraindicates implant placement.
- Pregnancy.
- Medication that affects bone healing.
- Psychological problems.
- Patient had undergone radiation therapy to the head and neck area in the past 12 months.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Influence of Acellular Dermal Matrix on Peri-implant Soft Tissue Phenotype and Marginal Bone Loss Following Immediate Implant Placement in Anterior Maxilla: A Randomized Controlled Clinical Trial
To evaluate soft tissue augmentation using acellular dermal matrix (ADM) over immediately placed dental implants in anterior maxilla.
Read the detailed description
This randomized clinical trial was designed to evaluate and compare the efficacy of ADM versus d-PTFE membranes in the preservation of the peri-implant hard and soft tissues in the setting of immediate implant placement on the anterior maxilla.
- Conditions
- Immediate Dental Implant Placement, Dental Implant, Acellular Dermal Matrix, Polytetrafluoroethylene, Soft Tissue Augmentation at Dental Implants
- Being tested
- Polytetrafluoroethylene coverage, Acellular Dermal Matrix
- Keywords
- Acellular Dermal Matrix, Immediate Dental Implants, Soft-tissue augmentation, Tissue Phenotype, d-PTFE
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Polytetrafluoroethylene coverageProcedure or surgery
The socket with immediately placed dental implant was covered with a d-PTFE membrane cut to fit the surgical site
Acellular Dermal MatrixProcedure or surgery
The socket with immediately placed dental implant was covered with ADM that was inserted into facial and palatal split thickness pouches.
| Study group | Role | What they receive |
|---|---|---|
| Control Group | Experimental | Immediately placed dental implants with high-density polytetrafluorethylene membrane coverage Receives: Procedure: Polytetrafluoroethylene coverage |
| Test Group | Experimental | Immediately placed dental implants with acellular dermal matrix allograft coverage Receives: Procedure: Acellular Dermal Matrix |
What is being measured
The primary outcome is the main question the study is designed to answer.
Peri-implant soft-tissue phenotype
A standardized periodontal probe was used to clinically measure the keratinized mucosal width, supracrestal tissue height, and mucosal thickness. They were measured in millimeters (mm)
Measured: Six months following implant placement
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 May 2026
- Study start1 Apr 2025
- Primary completion1 Dec 2025
- Study completion1 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Immediate Dental Implant PlacementStudies of the same condition, open and under way.
- More trials run by Mansoura UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mansoura University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07573020
- Sponsor's protocol ID
- R.26.04.114
- Acronym
- ADM
- Status last verified
- May 2026
- First submitted
- 1 May 2026
- Last updated
- 7 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Haggag MA, Alrawooji MF, Attia AMM. Influence of acellular dermal matrix on peri-implant soft tissue phenotype and marginal bone loss following immediate implant placement in the anterior maxilla: a randomized controlled clinical trial. BMC Oral Health. 2026 Nov 4;26(1):2191. doi: 10.1186/s12903-026-10072-4.
PubMed 42983382
Study at a glance
From the registry record, last updated by the sponsor on 7 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Influence of Acellular Dermal Matrix on Peri-implant Soft Tissue Phenotype and Marginal Bone Loss Following Immediate Implant Placement in Anterior Maxilla: A Randomized Controlled Clinical Trial
- ClinicalTrials.gov ID
- NCT07573020
- Acronym / sponsor ID
- ADM / R.26.04.114
- Conditions
- Immediate Dental Implant Placement, Dental Implant, Acellular Dermal Matrix, Polytetrafluoroethylene, Soft Tissue Augmentation at Dental Implants
- Keywords
- Acellular Dermal Matrix, Immediate Dental Implants, Soft-tissue augmentation, Tissue Phenotype, d-PTFE
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Mansoura UniversityUniversity, hospital or other
- Study start
- 1 Apr 2025 (actual)
- Primary completion
- 1 Dec 2025 (actual)
- Study completion
- 1 Mar 2026 (actual)
- First posted
- 7 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate soft tissue augmentation using acellular dermal matrix (ADM) over immediately placed dental implants in anterior maxilla.
Detailed description
This randomized clinical trial was designed to evaluate and compare the efficacy of ADM versus d-PTFE membranes in the preservation of the peri-implant hard and soft tissues in the setting of immediate implant placement on the anterior maxilla.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control Group | Experimental | Procedure: Polytetrafluoroethylene coverageImmediately placed dental implants with high-density polytetrafluorethylene membrane coverage |
| Test Group | Experimental | Procedure: Acellular Dermal MatrixImmediately placed dental implants with acellular dermal matrix allograft coverage |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Patients with non-restorable maxillary anterior tooth/teeth.
- Good oral hygiene.
- Patients' cooperation and fully capable to comply with the study protocol.
- Age ranges from 18 to 45 years.
- Free from history of parafunctional habits e.g. clenching and bruxism
Key exclusion criteria (5 listed)
- Any local pathological condition that contraindicates implant placement.
- Pregnancy.
- Medication that affects bone healing.
- Psychological problems.
- Patient had undergone radiation therapy to the head and neck area in the past 12 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Polytetrafluoroethylene coverageThe socket with immediately placed dental implant was covered with a d-PTFE membrane cut to fit the surgical site | Procedure or surgery | Control Group |
| Acellular Dermal MatrixThe socket with immediately placed dental implant was covered with ADM that was inserted into facial and palatal split thickness pouches. | Procedure or surgery | Test Group |
Primary outcome
Peri-implant soft-tissue phenotype
Time frame: Six months following implant placement
A standardized periodontal probe was used to clinically measure the keratinized mucosal width, supracrestal tissue height, and mucosal thickness. They were measured in millimeters (mm)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 May 2026.
- Derived from this study: PubMed 42983382Haggag MA, Alrawooji MF, Attia AMM. Influence of acellular dermal matrix on peri-implant soft tissue phenotype and marginal bone loss following immediate implant placement in the anterior maxilla: a randomized controlled clinical trial. BMC Oral Health. 2026 Nov 4;26(1):2191. doi: 10.1186/s12903-026-10072-4.
- Individual participant dataSharing planned: No
Related trials for Immediate Dental Implant Placement
Active, not recruiting
The Aim of the Study Will be Clinically and Radio Graphically Comparison of Two Implant Designs Used to Treat Atrophied Mandible . Implant Design Comparison Will Done for Implant Stability,Peri-implant Soft Tissue Health Changes and Bone Changes .Patients Will be Divided Randomly Into Two Group
Dental Implant Bone Loss, Peri-Implant Health
RecruitingPhase 2/3
Lactoferrin Nanohydrogel for Soft And Hard Tissue Healing and Implant Stability in Immediate Implant Placement
Dental Implant, Wound Healing
Not yet recruiting
Immediate vs Conventional Loading With Different Crown Materials on Immediately Placed Single Implants
Partial Edentulism, Dental Implant
Recruiting
Melatonin Effect on Immediate Dental Implants in the Posterior Mandible
Dental Implant, Immediate Dental Implant Placement
Not yet recruiting
Do Immediate Digital Workflows Increase Patient Value?
Dental Implant, Implant Therapy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Polytetrafluoroethylene coverage and Acellular Dermal Matrix in people with Immediate Dental Implant Placement and Dental Implant, run by Mansoura University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Peri-implant soft-tissue phenotype (time frame: Six months following implant placement). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07573020, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 May 2026.